AR084229A2 - Preparado polifasico para la contracepcion a base de un estrogeno natural - Google Patents

Preparado polifasico para la contracepcion a base de un estrogeno natural

Info

Publication number
AR084229A2
AR084229A2 ARP110104615A ARP110104615A AR084229A2 AR 084229 A2 AR084229 A2 AR 084229A2 AR P110104615 A ARP110104615 A AR P110104615A AR P110104615 A ARP110104615 A AR P110104615A AR 084229 A2 AR084229 A2 AR 084229A2
Authority
AR
Argentina
Prior art keywords
units
daily doses
estradiolvalerate
dose
polyphasic
Prior art date
Application number
ARP110104615A
Other languages
English (en)
Inventor
Bernd Dsterberg
Jan Endrikat
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34979546&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR084229(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of AR084229A2 publication Critical patent/AR084229A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Steroid Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

Reivindicación 1: Preparado polifásico para la contracepción caracterizado porque la primera fase consiste en 2 unidades de dosis diarias del estrógeno natural, estradiolvalerato, de 3 mg cada una; la segunda fase consiste en 2 grupos de unidades de dosis diarias donde el primer grupo consiste en 5 unidades de dosis diarias de una combinación de 2 mg de estradiolvalerato y por lo menos el doble o el triple de la dosis anovulatoria de un gestágeno sintético, y el segundo grupo consiste en 17 unidades de dosis diarias de una combinación de 2 mg de estradiolvalerato y por lo menos el triple o el cuádruple de la dosis anovulatoria de un gestágeno sintético; una tercera fase de 2 unidades de dosis diarias que contienen 1 mg de estradiolvalerato cada una; y otra fase consistente en 2 unidades de dosis diarias de un placebo farmacéuticamente inocuo.Reivindicación 2: Preparado polifásico de acuerdo con la reivindicación 1, caracterizado porque la sustancia activa gestágena es dienogest, drospirenona o un gestágeno con por lo menos el doble de su dosis anovulatoria conocida.
ARP110104615A 2004-04-20 2011-12-12 Preparado polifasico para la contracepcion a base de un estrogeno natural AR084229A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004019743A DE102004019743B4 (de) 2004-04-20 2004-04-20 Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens

Publications (1)

Publication Number Publication Date
AR084229A2 true AR084229A2 (es) 2013-05-02

Family

ID=34979546

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP050101553A AR048830A1 (es) 2004-04-20 2005-04-20 Preparado polifasico para la contracepcion a base de un estrogeno natural y un gestageno sintetico
ARP110104615A AR084229A2 (es) 2004-04-20 2011-12-12 Preparado polifasico para la contracepcion a base de un estrogeno natural

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP050101553A AR048830A1 (es) 2004-04-20 2005-04-20 Preparado polifasico para la contracepcion a base de un estrogeno natural y un gestageno sintetico

Country Status (38)

Country Link
US (3) US8071577B2 (es)
EP (1) EP1740163B2 (es)
JP (1) JP4908399B2 (es)
KR (1) KR20060134168A (es)
CN (1) CN1946383B (es)
AR (2) AR048830A1 (es)
AT (1) ATE473734T1 (es)
AU (1) AU2005235418C1 (es)
BR (1) BRPI0510005A (es)
CA (1) CA2561839C (es)
CR (1) CR8695A (es)
CY (1) CY1111292T1 (es)
DE (2) DE102004019743B4 (es)
DK (1) DK1740163T4 (es)
EA (1) EA010313B1 (es)
EC (1) ECSP067000A (es)
ES (1) ES2348038T5 (es)
GT (1) GT200500093A (es)
HK (1) HK1099701A1 (es)
HR (1) HRP20100513T4 (es)
IL (2) IL178510A (es)
ME (1) ME01183B (es)
MX (1) MXPA06012213A (es)
MY (1) MY143669A (es)
NO (1) NO344098B1 (es)
NZ (1) NZ550417A (es)
PA (1) PA8630901A1 (es)
PE (1) PE20060308A1 (es)
PL (1) PL1740163T5 (es)
PT (1) PT1740163E (es)
RS (1) RS51434B2 (es)
SI (1) SI1740163T2 (es)
SV (1) SV2006002090A (es)
TW (1) TWI351960B (es)
UA (1) UA83915C2 (es)
UY (1) UY28863A1 (es)
WO (1) WO2005102247A2 (es)
ZA (1) ZA200609594B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004019743B4 (de) 2004-04-20 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens
EP1937274B1 (de) * 2005-10-13 2012-02-22 Bayer Pharma Aktiengesellschaft Verwendung von estradiolvalerat in kombination mit dienogest zur oralen therapie der dysf unktionellen uterinen blutung in einheit mit einer oralen kontrazeption
PT1787649E (pt) * 2005-10-13 2009-05-08 Bayer Schering Pharma Ag Utilização de valerato de estradiol em combinação com dienogest para a terapia oral da hemorragia uterina disfuncional em conjunto com uma contracepção oral
US8153616B2 (en) * 2005-10-17 2012-04-10 Bayer Pharma Aktiengesellschaft Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
US8063030B2 (en) 2006-03-02 2011-11-22 Warner Chilcott Company, Llc Extended cycle multiphasic oral contraceptive method
DE102006010329A1 (de) * 2006-03-06 2007-09-13 Höltge, Michael, Dipl.-Med. Hormonelles Kontrazeptivum auf der Basis eines Estrogens, eines Gestagens oder einer Kombination von Estrogenen und Gestagenen unter der Zugabe von Testosteron
EP1930010A1 (de) * 2006-10-20 2008-06-11 Bayer Schering Pharma Aktiengesellschaft Verwendung von Estradiolvalerat oder 17ß-Estradiol in Kombination mit Dienogest zur oralen Therapie für den Erhalt und/oder die Steigerung der weiblichen Libido
US20090117184A1 (en) * 2007-11-05 2009-05-07 Sabine Fricke Use of a gestagen in combination with an estrogen and one or more pharmaceutically acceptable auxiliary agents/excipients for lactose-free oral contraception
AR086395A1 (es) * 2011-05-11 2013-12-11 Kirax Corp Envase para el tratamiento de patologias

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4168068A (en) 1969-07-22 1971-01-28 Unisearch Limited Improvements in or relating to oral contraceptives
US3639600A (en) 1969-08-28 1972-02-01 Upjohn Co Process of establishing cyclicity in a human female
US3795734A (en) 1970-04-20 1974-03-05 American Home Prod Cyclic regimen of hormone administration for contraception
US4066757A (en) 1973-03-26 1978-01-03 Ortho Pharmaceutical Corporation Oral contraceptive regimen
DE2365103C3 (de) 1973-12-21 1980-08-28 Schering Ag, 1000 Berlin Und 4619 Bergkamen V erwendung von Hormonen zur Kontrazeption
DE2431704A1 (de) 1974-07-02 1976-01-22 Asche Ag Stufenkombinationspraeparate per kontrazeption
DE2645307A1 (de) 1976-10-05 1978-04-06 Schering Ag Neue mittel und neue methoden zur behandlung klimakterischer ausfallerscheinungen
JPS6019734B2 (ja) 1977-05-12 1985-05-17 三共株式会社 安定なプロスタグランジンe類製剤の製法
US4272270A (en) 1979-04-04 1981-06-09 Petrochem Consultants, Inc. Cryogenic recovery of liquid hydrocarbons from hydrogen-rich
NL8001593A (nl) * 1980-03-18 1981-10-16 Akzo Nv Meerfasisch combinatiepreparaat voor orale anticonceptie.
US4390531A (en) 1981-08-10 1983-06-28 Syntex Pharmaceuticals International Ltd. Method of contraception using peak progestogen dosage
US4921843A (en) 1988-10-20 1990-05-01 Pasquale Samuel A Contraception system and method
US4628051A (en) 1983-09-26 1986-12-09 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4530839A (en) 1983-09-26 1985-07-23 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4616006A (en) 1983-09-26 1986-10-07 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4544554A (en) 1983-09-26 1985-10-01 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
DE3341638A1 (de) 1983-11-17 1984-05-03 Hermann Dr.rer.nat. 8000 München Heßlinger Dreiphasen-praeparat zur empfaengnisverhuetung aus ethinyloestradiol und lynestrenol
DE3347125A1 (de) 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen Mehrstufenkombinationspraeparat und seine verwendung zur oralen kontrazeption
AU581486B2 (en) 1985-12-30 1989-02-23 Warner-Lambert Company Graduated estrogen contraceptive
IE61236B1 (en) 1986-07-15 1994-10-19 American Home Prod Combination dosage form for pre-menopausal women
CA2005933A1 (en) 1989-01-09 1990-07-09 Jesse Hipps, Sr. Photohardenable composition containing five member aromatic group with imine moiety
IE71203B1 (en) * 1990-12-13 1997-02-12 Akzo Nv Low estrogen oral contraceptives
DE4104385C1 (es) 1991-02-09 1992-08-13 Marika Dr.Med. 6509 Framersheim De Ehrlich
DE4224534A1 (de) 1992-07-24 1994-01-27 Marika Dr Med Ehrlich Ovulationshemmendes Mittel zur hormonalen Kontrazeption
DE4308406C1 (de) 1993-03-12 1994-06-16 Jenapharm Gmbh Kombinationspräparat zur Kontrazeption
DE4313926A1 (de) * 1993-04-28 1994-11-03 Jenapharm Gmbh Pharmazeutisches Mehrphasenpräparat zur hormonalen Kontrazeption
DE4339934C2 (de) 1993-05-07 1995-05-24 Klaus Dr Med Umbreit Ovulationshemmendes Mittel zur hormonalen Kontrazeption
NL9301562A (nl) 1993-09-09 1995-04-03 Saturnus Ag Preparaat voor substitutietherapie.
DE4344462C2 (de) 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
DE4429374C1 (de) 1994-08-12 1996-02-01 Jenapharm Gmbh Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente
DE19525017A1 (de) * 1995-06-28 1997-01-02 Schering Ag Pharmazeutisches Kombinatonspräparat, Kit und Methode zur hormonalen Kontrazeption
DE19540253C2 (de) * 1995-10-28 1998-06-04 Jenapharm Gmbh Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene
US20050032756A1 (en) 1995-10-28 2005-02-10 Michael Dittgen Multistage preparation for contraception based on natural estrogens
EP0917466B1 (en) 1996-07-26 2004-10-06 Wyeth Oral contraceptive
CN1186023C (zh) * 1996-07-26 2005-01-26 惠氏公司 双相避孕方法及包含孕激素和雌激素组合物的药剂盒
ES2223081T3 (es) 1996-07-26 2005-02-16 Wyeth Metodo anticonceptivo oral monofasico y kit que comprende una combinacion de progestina y estrogeno.
US6987101B1 (en) 1996-12-20 2006-01-17 Schering Aktiengesellschaft Therapeutic gestagens for the treatment of premenstrual dysphoric disorder
DE19654609A1 (de) 1996-12-20 1998-06-25 Schering Ag Therapeutische Gestagene zur Behandlung von Premenstrual Dysphoric Disorder
US5898032A (en) 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
US6312772B1 (en) * 1997-10-20 2001-11-06 Hoechst Celanese Corporation Multilayer laminate formed from a substantially stretched non-molten wholly aromatic liquid crystalline polymer and non-polyester thermoplastic polymer
DE19908762A1 (de) * 1999-02-18 2000-08-31 Jenapharm Gmbh Verwendung von Dienogest in hoher Dosierung
DE10045380A1 (de) 2000-09-14 2002-04-04 Schering Ag Verfahren zur Kontrazeption und dessen Darreichungsform
US6699820B2 (en) 2001-03-02 2004-03-02 Hartmut Ulrich Bielefeldt Method for making a superconductor with enhanced current carrying capability
DE10294402D2 (de) 2001-09-29 2004-11-11 Solvay Pharm Gmbh Estrogen-Gestagen Kombinationspräparat und Anwendung
EP1462106A1 (en) 2003-03-28 2004-09-29 Pantarhei Bioscience B.V. Pharmaceutical compositions and kits comprising 17-beta-estradiol and a progesteron for the treatment of gynecological disorders
JP2007528358A (ja) * 2003-06-25 2007-10-11 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト ジエノゲストを含んでなるホルモン置換療法および抑鬱療法
DE102004019743B4 (de) 2004-04-20 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens
BRPI0516247A (pt) 2004-10-07 2008-08-26 Duramed Pharmaceuticals Inc métodos de tratamento hormonal, utilizando regimes de ciclo prolongado de dose crescente
TW200726473A (en) 2005-06-28 2007-07-16 Wyeth Corp Compositions and methods for treatment of cycle-related symptoms
PT1787649E (pt) 2005-10-13 2009-05-08 Bayer Schering Pharma Ag Utilização de valerato de estradiol em combinação com dienogest para a terapia oral da hemorragia uterina disfuncional em conjunto com uma contracepção oral
US8153616B2 (en) 2005-10-17 2012-04-10 Bayer Pharma Aktiengesellschaft Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
EP1930010A1 (de) 2006-10-20 2008-06-11 Bayer Schering Pharma Aktiengesellschaft Verwendung von Estradiolvalerat oder 17ß-Estradiol in Kombination mit Dienogest zur oralen Therapie für den Erhalt und/oder die Steigerung der weiblichen Libido

Also Published As

Publication number Publication date
RS51434B2 (sr) 2020-11-30
MXPA06012213A (es) 2007-01-17
SV2006002090A (es) 2006-02-15
ATE473734T1 (de) 2010-07-15
AU2005235418B2 (en) 2009-08-06
CY1111292T1 (el) 2015-08-05
IL178510A0 (en) 2007-02-11
AR048830A1 (es) 2006-05-31
UY28863A1 (es) 2005-11-30
PL1740163T5 (pl) 2020-10-05
EP1740163B2 (de) 2020-01-15
HRP20100513T1 (en) 2010-11-30
DK1740163T3 (da) 2010-10-18
IL239861A0 (en) 2015-08-31
US20100173877A1 (en) 2010-07-08
MY143669A (en) 2011-06-30
ECSP067000A (es) 2006-12-29
SI1740163T2 (sl) 2020-04-30
CA2561839C (en) 2009-09-29
US20070259840A1 (en) 2007-11-08
NZ550417A (en) 2010-01-29
KR20060134168A (ko) 2006-12-27
ZA200609594B (en) 2008-04-30
DK1740163T4 (da) 2020-04-06
PL1740163T3 (pl) 2010-12-31
RS51434B (en) 2011-04-30
SI1740163T1 (sl) 2010-11-30
NO344098B1 (no) 2019-09-02
WO2005102247A2 (de) 2005-11-03
PT1740163E (pt) 2010-09-28
TW200534860A (en) 2005-11-01
PA8630901A1 (es) 2006-05-16
EA010313B1 (ru) 2008-08-29
WO2005102247A3 (de) 2006-01-12
AU2005235418C1 (en) 2015-05-21
AU2005235418A1 (en) 2005-11-03
IL178510A (en) 2015-08-31
EP1740163B1 (de) 2010-07-14
ES2348038T5 (es) 2020-09-14
HK1099701A1 (en) 2007-08-24
UA83915C2 (ru) 2008-08-26
ME01183B (me) 2013-03-20
CN1946383A (zh) 2007-04-11
EP1740163A2 (de) 2007-01-10
JP4908399B2 (ja) 2012-04-04
DE502005009904D1 (de) 2010-08-26
DE102004019743A1 (de) 2005-11-24
JP2007533681A (ja) 2007-11-22
HRP20100513T4 (hr) 2020-10-02
ES2348038T3 (es) 2010-11-29
BRPI0510005A (pt) 2007-09-18
GT200500093A (es) 2006-04-17
TWI351960B (en) 2011-11-11
CR8695A (es) 2008-07-29
US20110124612A1 (en) 2011-05-26
US8071577B2 (en) 2011-12-06
NO20065292L (no) 2007-01-17
CA2561839A1 (en) 2005-11-03
EA200601844A1 (ru) 2007-04-27
PE20060308A1 (es) 2006-05-25
CN1946383B (zh) 2010-06-09
DE102004019743B4 (de) 2008-11-27

Similar Documents

Publication Publication Date Title
AR084229A2 (es) Preparado polifasico para la contracepcion a base de un estrogeno natural
CO6160297A2 (es) Uso de valerato de estradiol o 17beta-estradiol en combinacion de dienogest en una terapia oral para mantener y/o incrementar la libido femenina
RS50262B2 (sr) Farmaceutska kombinacija etinilestradiola i drospirenona za primenu kao kontraceptivnog sredstva
NO327588B1 (no) Farmasoytisk sammensetning og preparat omfattende etinylostradiol og drospirenon for anvendelse som antikonsepsjonsmiddel
AR061959A1 (es) Composicion farmaceutica para la anticoncepcion y para reducir el riesgo de malformaciones congenitas
AR056694A1 (es) Uso de valerato de estradiol en combinacion con dienogest para la terapia oral de la hemorragia uterina disfuncional unida con una anticoncepcion oral
Medhus et al. Mianserin added to tricyclic antidepressants in depressed patients not responding to a tricyclic antidepressant alone: a randomized, placebo-controlled, double-blind study
NO20072893L (no) Fast, peroralt prevensjonsmiddel
DOP2006000035A (es) Preparación farmaceútica para la anticoncepción oral
DOP2006000037A (es) Forma farmacológica peroral sólida para la anticoncepción
CY1112775T1 (el) Χρηση βαλεριανικης οιστραδιολης σε συνδυασμο με dienogest για την απο του στοματος θεραπεια της δυσλειτουργικης αιμορραγιας της μητρας σε ενοτητα με αντισυλληψη απο του στοματος
UY29378A1 (es) Preparación farmaceutica para la anticoncepción oral
Tonato et al. Management of Nausea and Vomiting
AR072246A1 (es) Regimen de drospirenona /17 beta -estradiol, producto farmaceutico combinado y conjunto de elementos ( kit) para su aplicacion
CO5280075A1 (es) Drospirenona para terapia de reemplazo de hormonas
TH54054B (th) สารผสมทางเภสัชกรรมสำหรับใช้เป็นยาคุมกำเนิด
CL2009000608A1 (es) Producto farmaceutico combinado trifasico con 24 unidades de dosificacion, en donde la cantidad de drospirenona de la primera a la tercera fase disminuye de 3 mg a 1,5 mg y la cantidad de 17 beta-estradiol aumenta de 1 mg a 2 mg, ademas de 4 unidades de dosificacion de placebo o sin unidades de dosificacion; kit farmaceutico.
ECSP003721A (es) Una composicion farmaceutica para ser usada como anticonceptivo
TH80557B (th) ผลิตภัณฑ์ทางเภสัชกรรมสำหรับการคุมกำเนิดทางช่องปาก

Legal Events

Date Code Title Description
FC Refusal